Evaluation of WIRION™ EPS in Lower Extremities Arteries
Evaluation of WIRION™ EPS in Lower Extremities Arteries
Demonstrate the safety and performance of the WIRION™ EPS in subjects undergoing lower
 extremity atherectomy for the treatment of Peripheral Arterial Disease (PAD)
Inclusion Criteria:

 1. Subject is at least 18 years of age

 2. Subject or authorized representative, signed a written Informed Consent form to
 participate in the study, prior to any study related procedures

 3. Subject is willing to comply with the protocol requirements and return to the
 treatment center for all required clinical evaluations

 4. Rutherford classification 2-4

 5. Has moderate to severe calcification visualized on angiogram in the femoropopliteal
 arteries

 6. Planned atherectomy of the native femoropopliteal arteries

 7. Reference vessel diameter for intended filter location must be visually estimated to
 be ≥3.5mm and ≤6.0mm

 8. An adequate "landing zone" for placement of the WIRION™ device distal to the target
 lesion of at least 30mm

 9. A female subject is eligible if not of child bearing potential or has a negative
 pregnancy test within the previous 7 days and agrees to remain on birth control
 throughout the study

 Exclusion Criteria:

 1. Any planned surgical or endovascular intervention within 30 days before or after the
 index procedure

 2. A lesion deemed not accessible by the WIRION™ EPS

 3. Inability to take aspirin or ADP receptor antagonists

 4. History of bleeding diathesis or coagulopathy or will refuse blood transfusion if
 deemed necessary

 5. Has perforation, dissection, or other injury of the access or target vessel requiring
 additional stenting or surgical intervention before enrollment

 6. Subject is enrolled in another drug or device study protocol that has not reached its
 primary endpoint (participating in registry studies is not excluded)

 7. Life expectancy less than 12 months

 8. Known severe renal insufficiency (eGFR <30 ml/min/1.72m2).

 9. ≤1-vessel tibial run-off status